Detection of malignancies of head and neck cancer using PET and change induced by radiation therapy

使用 PET 检测头颈癌恶性肿瘤和放射治疗引起的变化

• 批准号: 07672056
• 负责人: SHOZUSHIMA Masanori
• 金额: $ 1.54万
• 依托单位: Iwate medical university
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1995
• 资助国家: 日本
• 起止时间: 1995 至 1996
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-07672056/
• 关键词: Head and neck; malignant tumor; FDG; PET; 頭頚部; 頭頚部悪性腫瘍

The positron emission tomography (PET) tracer 2-18F-fluoro-2-deoxy-D-glucose (FDG) is the most widely used tracer in oncology. This study was undertaken to evaluate PET in the detection of head and neck malignancies, compared to analysis of MRI,CT and histopathological findings.A total of 17 patients with malignant tumors were examined with FDG.PET revealed that each biopsy-proven primary lesion is an area of increased FDG uptake. Metastatic lymph node has been demonstrated in two cases by the pathologic findings. The smallest metastatic lymph node detected in the retropharyngeal space by FDG-PET was 4mm. The uptake of FDG in lymph nodes were studied from 10 to 60 min after a injection of FDG.Metastatic lymph node uptake increased gradually after injection, whereas reactive node uptake decreased. The FDG uptake ratio was seemed depend on the rate between tumor cells and interstitial tissue in malignant lesion. In this series, the authors found that FDG-PET is a useful diagnostic modality for evaluation the patient with head and neck cancers.

正电子发射断层扫描（PET）示踪剂2-18F-Fluoro-2-脱氧-D-葡萄糖（FDG）是肿瘤学中使用最广泛的示踪剂。与MRI，CT和组织病理学发现的分析相比，这项研究是为了评估头颈恶性肿瘤的检测PET。总共用FDG检查了17例恶性肿瘤患者。 FDG吸收增加的区域。在两种情况下，通过病理学发现证明了转移性淋巴结。 FDG-PET在咽后空间中检测到的最小转移性淋巴结为4mm。注射FDG后的10至60分钟，研究了FDG在注射后的10到60分钟。注入后的转移性淋巴结摄取逐渐增加，而反应性节点的摄取减少。 FDG摄取比似乎取决于恶性病变中肿瘤细胞和间质性组织之间的速率。在本系列中，作者发现FDG-PET是评估头颈癌患者的有用诊断方式。